Does Medicaid Cover Ozempic and GLP-1 Drugs? (2026)

Direct Answer: Why Indication Determines Everything

It depends on the FDA-approved reason the drug is prescribed. Ozempic (semaglutide) is FDA-approved for type 2 diabetes management and most state Medicaid programs cover it for that indication with prior authorization. Ozempic is NOT approved by the FDA for weight loss, and Medicaid will not cover it for off-label weight-loss use in patients without diabetes. Wegovy, a higher-dose semaglutide formulation approved for obesity, is covered by only 13 state Medicaid programs as of January 2026.

Ozempic vs. Wegovy: Same Molecule, Different Approvals

Both Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist. The drugs differ in dose and FDA approval. Ozempic is injected at 0.25 mg to 2 mg weekly and is FDA-approved (since 2017) for blood sugar control in type 2 diabetes and to reduce cardiovascular risk in adults with type 2 diabetes and heart disease. Wegovy is injected at up to 2.4 mg weekly and is FDA-approved (since 2021) for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. Medicaid drug coverage tracks the FDA-approved indication: Ozempic for diabetes, Wegovy for obesity.

Rybelsus, the oral semaglutide tablet (7 mg or 14 mg daily), is FDA-approved only for type 2 diabetes and follows the same Medicaid coverage pattern as Ozempic. In December 2025, the FDA also approved an oral Wegovy formulation for weight management, though Medicaid coverage for the oral obesity version is subject to the same limited state-by-state rules as injectable Wegovy.

Medicaid GLP-1 Coverage for Type 2 Diabetes: What Most States Require

Most state Medicaid programs include Ozempic on their preferred drug lists for type 2 diabetes, but coverage comes with prior authorization requirements that can be demanding. Medicaid prior authorization for Ozempic for diabetes typically requires documented type 2 diabetes diagnosis with supporting HbA1c lab results, evidence that the member has tried and failed at least one first-line medication such as metformin, prescription from an appropriate provider (primary care or endocrinologist), and regular reauthorization every 3 to 6 months to demonstrate ongoing treatment effectiveness.

Medicaid programs also cover Ozempic for two additional FDA-approved cardiovascular indications: reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established heart disease, and (for semaglutide specifically) reducing the risk of kidney disease progression. Coverage for these indications follows state-specific preferred drug list policies, so check with your state Medicaid managed care plan for current requirements.

State-by-State GLP-1 Weight Loss Coverage (2026)

Medicaid GLP-1 weight loss coverage varies significantly by state. Only 13 states cover GLP-1 drugs for obesity under fee-for-service Medicaid as of January 2026, down from 16 states in 2025. The 13 states are Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, and Wisconsin. All 13 require prior authorization for obesity coverage.

Four states dropped GLP-1 obesity coverage on January 1, 2026: California (Medi-Cal removed Wegovy and Zepbound from its contract drugs list for weight loss indications), New Hampshire, Pennsylvania, and South Carolina. Medi-Cal continues to cover semaglutide for type 2 diabetes, cardiovascular disease, and obstructive sleep apnea with prior authorization. Massachusetts (MassHealth) is also reducing ongoing weight-loss GLP-1 coverage effective July 1, 2026; enrollees currently covered should verify their renewal status with MassHealth.

The CMS BALANCE Model: What Changes in May 2026

The Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model launched by CMS in December 2025 is a voluntary 5-year test designed to expand Medicaid access to GLP-1 drugs for obesity. State Medicaid agencies can join beginning in May 2026, with state applications due by July 31, 2026, with coverage beginning January 1, 2027. The model runs through December 2031. Under BALANCE, CMS negotiates lower GLP-1 drug prices directly with eligible manufacturers on behalf of participating state Medicaid agencies, potentially making obesity GLP-1 coverage financially viable for states that currently cannot afford it.

Participation in the BALANCE model is voluntary for state Medicaid agencies, Medicare Part D plans, and drug manufacturers. All Medicaid beneficiaries receiving a GLP-1 for weight management under BALANCE must also be enrolled in a lifestyle support program provided by the manufacturer at no cost. States that choose to participate would expand access for their Medicaid population to GLP-1 obesity drugs at negotiated lower costs. The BALANCE model does not change the diabetes coverage rules, which remain separately governed by each state's preferred drug list.

What Ozempic Costs Without Medicaid Coverage in 2026

Ozempic's 2026 list price is approximately $1,027 per pen (each pen contains a month's supply for most doses). Manufacturer savings programs through Novo Nordisk bring out-of-pocket cost down to roughly $199 per month for the first two months (0.25 mg and 0.5 mg doses) and $349 to $499 per month for maintenance doses, but these programs are NOT available to Medicaid or Medicare beneficiaries. The Ozempic Savings Card explicitly excludes federal program enrollees.

Wegovy's 2026 list price is approximately $1,349 per month. For Medicaid beneficiaries in states without obesity GLP-1 coverage, alternatives include: Federally Qualified Health Centers (FQHCs) that can access the 340B drug pricing program for discounted medications; patient assistance programs directly through Novo Nordisk for uninsured individuals who meet income requirements; and, for eligible individuals, state pharmaceutical assistance programs that vary by state. Always ask your prescriber about formulary alternatives or whether a prior authorization appeal is warranted.

Alternatives If Your State Does Not Cover GLP-1 Drugs for Weight Loss

Medicaid beneficiaries in states without GLP-1 obesity coverage have several options to explore. First, if you have type 2 diabetes, your physician can prescribe Ozempic for that FDA-approved indication and Medicaid will cover it in most states. Second, ask your prescriber whether older FDA-approved weight-loss medications that have been on the market longer are on your state's Medicaid formulary. Medications like phentermine/topiramate (Qsymia), naltrexone/bupropion (Contrave), or orlistat may be covered as lower-cost alternatives.

Third, check whether your state Medicaid managed care plan has broader coverage than the fee-for-service formulary. Managed care plans sometimes cover drugs not on the state FFS list. Fourth, ask your provider about the BALANCE model timeline. States joining in May 2026 or through January 2027 would expand obesity GLP-1 access, so it is worth asking your state Medicaid office whether your state intends to participate. Fifth, Federally Qualified Health Centers access 340B program pricing and may be able to supply GLP-1 drugs at significantly reduced cost to uninsured or underinsured patients.

How to Get Ozempic or Wegovy Covered by Medicaid: Prior Authorization Steps

For type 2 diabetes coverage, the prior authorization process follows a documented clinical pathway. For obesity coverage in states that offer it, prior authorization requirements are similarly strict. The fastest path is to work with your prescriber who handles these requests routinely.

• Step 1: Get a diagnosis. For diabetes coverage, you need a confirmed type 2 diabetes diagnosis (ICD-10 code E11.x) and recent HbA1c lab results. For obesity coverage, you need a BMI of 30 or higher, or 27 or higher with a qualifying comorbidity.
• Step 2: Document prior treatment. For diabetes, most states require documentation that metformin or another first-line agent was tried and failed or is contraindicated. For obesity, most states require documentation of failed dietary or behavioral interventions.
• Step 3: Your provider submits the prior authorization request to your Medicaid managed care plan with clinical documentation. Turnaround is typically 3 to 14 business days. Urgent requests may be approved in 24 to 72 hours when medically necessary.
• Step 4: If denied, appeal within 60 days. The denial notice must state the specific reason. Your provider can submit additional clinical documentation supporting medical necessity. You can also request a peer-to-peer review between your doctor and the plan's medical director.
• Step 5: Reauthorization is required every 3 to 6 months in most states. Keep lab results and weight records current. Your provider handles reauthorization using the same documented clinical evidence.

Does Medicaid cover Ozempic for type 2 diabetes in 2026?

Yes, most state Medicaid programs cover Ozempic (semaglutide) for type 2 diabetes with prior authorization in 2026. Your provider must document your diagnosis, HbA1c lab results, and typically show that first-line medications like metformin were tried first. Prior auth must be renewed every 3 to 6 months. Check your state's preferred drug list or call your Medicaid managed care plan to confirm current coverage.

Does Medicaid cover Ozempic for weight loss?

No. Medicaid does not cover Ozempic for weight loss because Ozempic is FDA-approved for type 2 diabetes, not for weight management. Prescribing it off-label for obesity in a patient without diabetes is not covered by Medicaid. Wegovy (the higher-dose semaglutide formulation approved for obesity) is covered by only 13 state Medicaid programs as of January 2026.

Which states cover Wegovy for weight loss under Medicaid in 2026?

As of January 2026, 13 states cover GLP-1 drugs for obesity under fee-for-service Medicaid: Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, and Wisconsin. Four states (California, New Hampshire, Pennsylvania, South Carolina) dropped obesity GLP-1 coverage on January 1, 2026. Massachusetts (MassHealth) is further reducing coverage effective July 1, 2026.

What is the difference between Ozempic and Wegovy for Medicaid coverage purposes?

Both Ozempic and Wegovy contain semaglutide but are FDA-approved for different uses. Ozempic is approved for type 2 diabetes and is covered by most state Medicaid programs for that indication. Wegovy is approved for chronic weight management and is covered only by 13 state Medicaid programs. Medicaid coverage tracks the FDA-approved indication, not the drug's active ingredient.

What is the CMS BALANCE model and does it affect Medicaid GLP-1 coverage?

The BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) model is a voluntary CMS initiative launching in May 2026 that allows state Medicaid agencies to join and receive negotiated lower drug prices for GLP-1 obesity medications. States can participate through January 2027 and the model runs through December 2031. Participation is voluntary and would expand obesity GLP-1 coverage in participating states at lower cost to the state.

How much does Ozempic cost if Medicaid does not cover it?

Ozempic's 2026 list price is approximately $1,027 per pen (one pen is roughly a month's supply). Manufacturer savings programs bring costs to $199 to $499 per month, but those programs explicitly exclude Medicaid and Medicare beneficiaries. Federally Qualified Health Centers (FQHCs) can access 340B drug pricing for significant discounts. Ask your FQHC provider about 340B pricing for GLP-1 drugs.

Does Medicaid cover Mounjaro or Zepbound (tirzepatide)?

Mounjaro (tirzepatide, FDA-approved for type 2 diabetes) is covered by most state Medicaid programs for diabetes with prior authorization, following the same rules as Ozempic. Zepbound (tirzepatide, FDA-approved for obesity) is covered only by the same 13 state Medicaid programs that cover Wegovy for obesity. The same FFS formulary rules and prior authorization requirements apply.

What happens if my Medicaid prior authorization for Ozempic is denied?

You have the right to appeal within 60 days of receiving the written denial notice. The denial must state the specific reason. Ask your provider to submit a peer-to-peer review request with your plan's medical director, which has a higher reversal rate than a standard written appeal. If internal appeal fails, you can request a state fair hearing through your state Medicaid office. Document all communications in writing.